Many facets of bortezomib resistance/susceptibility

Blood

Volumn 112, Issue 6, 2008, Pages 2177-2178

  Kumar, Shaji ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HEAT SHOCK PROTEIN 27; HISTONE DEACETYLASE INHIBITOR; PROTEASOME INHIBITOR; TUBACIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 61849152933     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-167767     Document Type: Article

References (8)

1. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003; 29(suppl 1):3-9,
2. Rajkumar SV, Richardson PG, Hideshima T, et al. Pro teasome inhibition asa novel therapeutic target in human cancer, J Clin Oncol. 2004;23:630-639,
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al, Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008; 111:2516-2520,
4. Richardson PG, Sonneveld P, Schuster M W, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-2498.
5. Wang L, Kumar S, Fridley BL, el al, Proteasome {beta} subunit pharmacogenomics: gene resequencing and functional genomics, Clin. Cancer Res. 2008; 14:
6. Hideshima T, Bradner JE, Wong J, et al. Smallmolecule inhibition of proleasome and aggresome function induces synergistic antitumor activity in multiple myeloma, Proc Natl Acad Sci U S A. 2005; 102:8567-8572,
7. Chauhan D, Li G, Shringarpure R, el al. Blockade of Hsp27 overcomes bortezomib/protcasome inhibitor PS 341 resistance in lymphoma cells. Cancer Res. 2003;63: 6174-6177.
8. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma, Cancer Cell. 2007;12:131-144.